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2008-2009 Influenza Season 
Week 34 ending August 29, 2009 
All data are preliminary and may change as more reports are received. 
Synopsis:  During week 34 (August 23-29, 2009), influenza activity increased in the United States. 
o Since mid-April to August 30, 2009, a total of 9,079 hospitalizations and 593 deaths 
associated with 2009 influenza A (H1N1) viruses have been reported to CDC an increase 
from 8,843 hospitalizations and 556 deaths from the prior week. 
o During week 34: 
o 1,109 (17.3%) specimens tested by U.S. World Health Organization (WHO) and National 
Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories and 
reported to CDC/Influenza Division were positive for influenza. 
o 97% of all subtyped influenza A viruses being reported to CDC were 2009 influenza A 
(H1N1) viruses. 
o One human infection with a novel influenza A virus was reported.  
o The proportion of deaths attributed to pneumonia and influenza (P&I) was below the 
epidemic threshold.  
o One influenza-associated pediatric death was reported and was associated with a 2009 
influenza A (H1N1) virus infection. 
o The proportion of outpatient visits for influenza-like illness (ILI) was below the national 
baseline. Region IV reported ILI above its region-specific baseline. 
o Six states and Puerto Rico reported geographically widespread influenza activity, 13 states 
reported regional influenza activity, 10 states and the District of Columbia reported local 
influenza activity, 19 states reported sporadic influenza activity, two states reported no 
influenza activity, and Guam and the U.S. Virgin Islands did not report. 
 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative for the season 
HHS 
Surveillance 
Regions* 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity§  
A (H1) A (H3) 
2009 A 
(H1N1) 
A  
(unable 
to sub-
type)¥ 
A 
(Subty-
ping 
not 
perfor-
med) 
B  Pediatric Deaths 
Nation Normal 17.3% 20 of 54 8,211 4,026 38,112 830 19,997 10,821 111 
Region I Normal 8.3% 0 of 6 585 305 2,933 13 1,706 820 4 
Region II Normal 2.9% 2 of 4 297 228 1,831 21 2,391 714 20 
Region III Normal 15.7% 2 of 6 1,251 220 4,378 20 1,045 1,363 10 
Region IV Elevated 19.9% 8 of 8 910 444 4,850 84 3,530 1,298 10 
Region V Normal 12.0% 0 of 6 1,661 212 8,365 199 884 1,422 18 
Region VI Normal 24.6% 2 of 5 830 309 3,698 7 5,013 2,667 16 
Region VII Normal 15.4% 1 of 4 537 86 1,149 118 553 537 0 
Region VIII Normal 13.8% 1 of 6 540 219 1,569 80 1,784 503 9 
Region IX Normal 24.3% 3 of 5 1,210 1,679 6,681 74 2,559 806 21 
Region X Normal 20.6% 1 of 4 390 324 2,658 214 532 691 3 
* HHS regions (Region I: CT, ME, MA, NH, RI, VT; Region II: NJ, NY, Puerto Rico, US Virgin Islands; Region III: DE, DC, MD, PA, VA, WV; Region IV: AL, FL, GA, KY, MS, NC, 
SC, TN; Region V: IL, IN, MI, MN, OH, WI; Region VI: AR, LA, NM, OK, TX; Region VII: IA, KS, MO, NE; Region VIII: CO, MT, ND, SD, UT, WY; Region IX: AZ, CA, Guam, HI, 
NV; and Region X: AK, ID, OR, WA) 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline 
‡ National data are for current week; regional data are for the most recent three weeks 
§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and U.S. Virgin Islands 
¥ The majority of influenza A viruses that cannot be sub-typed as seasonal influenza viruses are 2009 A (H1N1) influenza viruses upon further testing 
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U.S. Virologic Surveillance:  WHO and NREVSS collaborating laboratories located in all 50 states 
and Washington D.C. report to CDC the number of respiratory specimens tested for influenza and 
the number positive by influenza type and subtype. The results of tests performed during the 
current week are summarized in the table below. 
 
 
 Week 34 
No. of specimens tested 6,410 
No. of positive specimens (%) 1,109 (17.3%) 
Positive specimens by type/subtype  
Influenza A                1,105 (99.6%) 
          A (2009 H1N1)   755 (68.3%)  
          A (subtyping not performed)          311 (28.1%)
          A (unable to subtype)  18 (1.6%)  
          A (H3)                11 (1.0%)  
          A (H1) 10 (0.9%)
Influenza B                   4 (0.4%) 
 
 
During week 34, seasonal influenza A (H1) and A (H3) and B viruses co-circulated at low levels with 
2009 influenza A (H1N1) viruses.  97% of all subtyped influenza A viruses being reported to CDC 
this week were 2009 influenza A (H1N1) viruses. 
 
The unusually high percentage of specimens testing positive for influenza by WHO and NREVSS 
collaborating laboratories remained higher during week 34 than is typically seen this time of year, 
and may be due to a combination of factors including higher than normal circulation of influenza in 
the summer with the emergence of the 2009 H1N1 virus, changes in testing practices by health 
care providers, triaging of specimens by public health laboratories, an increase in the number of 
specimens collected from outbreaks, and other factors. 
 
As of September 4, 2009, 9,079 hospitalizations and 593 deaths (16 deaths in individuals 0-4 years, 
93 deaths in individuals 5-24 years, 249 deaths in adults 25-49 years, 171 deaths in adults 50-64 
years, 57 deaths in adults age 65 and older, and 7 deaths for which age was no reported) 
associated with 2009 influenza A (H1N1) virus have been identified by CDC and state and local 
public health departments (http://www.cdc.gov/h1n1flu/update.htm). 
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Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2008-09 
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Novel Influenza A Virus:  One case of human infection with a novel influenza A virus was reported 
by the Kansas Department of Health and Environment.  The case patient was infected with a swine 
influenza A (H3N2) virus and reported contact with pigs in the week preceding symptom onset, July 
28, 2009.  The patient did not require hospitalization and has fully recovered.  Although the 
investigation is ongoing, there does not appear to have been sustained human-to-human 
transmission with this virus.  Early identification and investigation of these cases is critical to 
evaluate the extent of the outbreak and possible human-to-human transmission.  Surveillance for 
human infections with novel influenza A viruses continues, even with the sustained community 
transmission of the 2009 H1N1 virus. 
Antigenic Characterization:  CDC has antigenically characterized 2,112 seasonal human 
influenza viruses [1,189 influenza A (H1), 227 influenza A (H3) and 696 influenza B viruses] 
collected by U.S. laboratories since October 1, 2008, and 493 2009 influenza A (H1N1) viruses. 
All 1,189 seasonal influenza A (H1) viruses are related to the influenza A (H1N1) component of the 
2008-09 influenza vaccine (A/Brisbane/59/2007).  Two hundred sixteen (95%) of 227 influenza A 
(H3N2) viruses tested are related to the A (H3N2) vaccine component (A/Brisbane/10/2007) and 11 
viruses (5%) tested showed reduced titers with antisera produced against A/Brisbane/10/2007.  
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All 493 2009 influenza A (H1N1) viruses are related to the A/California/07/2009 (H1N1)pdm   
reference virus selected by WHO as a potential candidate for 2009 influenza A (H1N1) vaccine. 
Influenza B viruses currently circulating can be divided into two distinct lineages represented by the 
B/Yamagata/16/88 and B/Victoria/02/87 viruses. Seventy-six (11%) of 696 influenza B viruses 
tested belong to the B/Yamagata lineage and are related to the vaccine strain (B/Florida/04/2006). 
The remaining 620 (89%) viruses belong to the B/Victoria lineage and are not related to the vaccine 
strain.  
Data on antigenic characterization should be interpreted with caution given that antigenic 
characterization data are based on hemagglutination inhibition (HI) testing using a panel of 
reference ferret antisera, and results may not correlate with clinical protection against circulating 
viruses provided by influenza vaccination. 
Annual influenza vaccination is expected to provide the best protection against those virus 
strains that are related to the vaccine strains, but limited to no protection may be expected when the 
vaccine and circulating virus strains are so different as to be from different lineages, as is seen with 
the two lineages of influenza B viruses.  Antigenic characterization of 2009 influenza A (H1N1) 
viruses indicates that these viruses are antigenically and genetically unrelated to seasonal influenza 
A (H1N1) viruses, suggesting that little to no protection would be expected from vaccination with 
seasonal influenza vaccine.  
Antiviral Resistance: Since October 1, 2008, 1,148 seasonal influenza A (H1N1), 255 influenza A 
(H3N2), 652 influenza B, and 560 2009 influenza A (H1N1) virus isolates have been tested for 
resistance to the neuraminidase inhibitors (oseltamivir and zanamivir).  In addition, 717 2009 
influenza A (H1N1) original clinical samples were tested for a single known mutation in the virus 
that confers oseltamivir resistance.  Also, 1,152 seasonal influenza A (H1N1), 252 influenza A 
(H3N2), and 486 2009 influenza A (H1N1) viruses have been tested for resistance to the 
adamantanes (amantadine and rimantadine).  Three state public health laboratories perform 
antiviral testing and report their results to CDC.  Two additional oseltamivir resistant 2009 influenza 
A (H1N1) viruses have been identified by these laboratories.  The results of antiviral resistance 
testing performed on these viruses are summarized in the table below. 
 
Resistant 
Viruses, 
Number (%) 
Resistant 
Viruses, 
Number (%) 
Resistant 
Viruses, 
Number (%)  Viruses tested (n) 
Oseltamivir 
Viruses 
tested (n) 
Zanamivir 
Viruses 
tested (n) 
Adamantanes 
Seasonal 
Influenza A 
(H1N1) 
1,148 1,143 (99.6%) 1,148 0 (0) 1,152 6 (0.5%) 
Influenza A 
(H3N2) 255 0 (0) 255 0 (0) 252 245 (100%) 
Influenza B 652 0 (0) 652 0 (0) N/A* N/A* 
2009 
Influenza A  
(H1N1) 
1,277 7†‡ (0.6) 560 0 (0) 486 486 (100%) 
*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses. 
†Two screening tools were used to determine oseltamivir resistance: sequence analysis of viral genes and a neuraminidase inhibition 
assay. 
‡ Three state public health laboratories perform antiviral resistance testing and report their results to CDC.  An additional two oseltamivir 
resistant 2009 influenza A (H1N1) viruses have been identified by these laboratories, bringing the total number to nine. 
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2009 influenza A (H1N1) viruses were tested for oseltamivir resistance by a neuraminidase 
inhibition assay and/or detection of genetic sequence mutation, depending on the type of specimen 
tested: original clinical samples were examined for a single known mutation in the virus that confers 
oseltamivir resistance in currently circulating seasonal influenza A (H1N1) viruses, while influenza 
virus isolates were tested using a neuraminidase inhibition assay that determines the presence or 
absence of neuraminidase inhibitor resistance, followed by the neuraminidase gene sequence 
analysis of resistant viruses.   
 
The majority of 2009 influenza A (H1N1) viruses are susceptible to the neuraminidase inhibitor 
antiviral medication oseltamivir, however rare sporadic cases of oseltamivir resistant 2009 influenza 
A (H1N1) viruses have been detected worldwide, including nine cases in the United States.  All 
tested viruses retain their sensitivity to the other neuraminidase inhibitor zanamivir.  Additional 
information on antiviral recommendations for treatment and chemoprophylaxis of 2009 influenza A 
(H1N1) infection is available at http://www.cdc.gov/h1n1flu/recommendations.htm.  All 2009 
influenza A (H1N1) viruses tested to date are resistant to the adamantane antiviral medications, 
amantadine and rimantadine. Antiviral treatment with either oseltamivir or zanamivir is 
recommended for all patients with confirmed, probable or suspected cases of 2009 influenza A 
(H1N1) virus infection who are hospitalized or who are at higher risk for seasonal influenza 
complications.   
 
Eight of the nine patients had documented exposure to oseltamivir through either treatment or 
chemoprophylaxis, and the remaining patient is currently under investigation to determine exposure 
to oseltamivir.  Occasional development of oseltamivir resistance during treatment or prophylaxis is 
not unexpected.  Enhanced surveillance is expected to detect additional cases of oseltamivir 
resistant 2009 influenza A (H1N1) viruses and such cases will be investigated to assess the spread 
of resistant strains in the community.  To prevent the spread of antiviral resistant virus strains, CDC 
reminds clinicians and the public of the need to continue hand and cough hygiene measures for the 
duration of any symptoms of influenza 
(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5832a3.htm).  
 
Three seasonal influenza A (H1N1) viruses collected between February 8 and May 11, 2009, were 
found to be resistant to both oseltamivir and the adamantanes (amantadine and rimantadine).  All 
seasonal influenza A (H1N1) viruses tested retain their sensitivity to zanamivir.  The three dually-
resistant viruses represent less than 1% of all seasonal influenza A (H1N1) viruses tested during 
the 2008-09 influenza season, and as a result, no changes to the influenza antiviral treatment or 
prophylaxis recommendations will be made at this time.  CDC will continue to monitor trends in 
antiviral resistance over the summer and throughout the upcoming 2009-10 influenza season.   
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 34, 5.8% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage was 
below the epidemic threshold of 6.3% for week 34. 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
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4
6
8
10
12
31 40 50 10 20 30 40 50 10 20 30 40 50 10 20 30 40 50 10 20 30
Weeks
%
 o
f A
ll 
D
ea
th
s 
D
ue
 to
 P
&
I
Epidemic Threshold
Seasonal Baseline
2007 200820062005 2009
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2008-2009 Influenza Season – Week 34, ending August 29, 2009           
 
7
 
Influenza-Associated Pediatric Mortality:  One influenza-associated pediatric death was reported 
to CDC during week 34 (New York).  This death was associated with 2009 influenza A (H1N1) virus 
infection.  The death reported this week occurred between June 14 and June 20, 2009.  Since 
September 28, 2008, CDC has received 111 reports of influenza-associated pediatric deaths that 
occurred during the current influenza season, 43 of which were due to 2009 influenza A (H1N1) 
virus infections. 
 
Of the 45 children who had specimens collected for bacterial culture from normally sterile sites, 17 
(37.8%) were positive; Staphylococcus aureus was identified in 11 (64.7%) of the 17 children.    
Five of the S. aureus isolates were sensitive to methicillin and six were methicillin resistant.  Fifteen 
(88.2%) of the 17 children with bacterial coinfections were five years of age or older and 11 (64.7%) 
of the 17 children were 12 years of age or older.  Fourteen (32.6%) of the 43 children with 
confirmed 2009 influenza A (H1N1) infection had a specimen collected from a normally sterile site; 
three (21.4%) of the 14 children had a positive bacterial culture (methicillin sensitive S. aureus, 
methicillin resistant S. aureus and Streptococcus constellatus).  
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
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Influenza-Associated Hospitalizations:  Laboratory-confirmed influenza-associated 
hospitalizations are monitored in two population-based surveillance networks: the New Vaccine 
Surveillance Network (NVSN) and the Emerging Infections Program (EIP). 
 
During October 12, 2008 to July 11, 2009, the preliminary laboratory-confirmed influenza-
associated hospitalization rate for children 0-4 years old in the NVSN was 4.42 per 10,000.  
Data collection for influenza-associated hospitalizations through the NVSN has been completed for 
the 2008-09 influenza season.  There will be no updates to this system. 
 
NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children 0 - 4 Years, 2008-09 and Previous Three Seasons 
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During April 15, 2009 – August 29, 2009, the following preliminary laboratory-confirmed overall 
influenza associated hospitalization rates were reported by the EIP (rates include influenza A, 
influenza B, and 2009 influenza A (H1N1)): 
 
Rates for children aged 0-23 months, 2-4 years, and 5-17 years were 2.4, 0.9, and 0.8 per 10,000, 
respectively.  Rates for adults aged 18-49 years, 50-64 years, and ≥ 65 years, the overall flu rates 
were 0.5, 0.6, and 0.5 per 10,000, respectively. 
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EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates, 
Spring/Summer 2009 
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*This value represents an age group-specific average influenza rate from October 1 to April 30 from the 2005-
06, 2006-07, and 2007-08 influenza seasons. 
**Note: The scales for the 0-23 month and the ≥65 year age groups differ from other age groups. 
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Outpatient Illness Surveillance: Nationwide during week 34, 2.1% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI).  This percentage is below the national baseline of 2.4%. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
National Summary, 2008-09 and Previous Two Seasons 
*There was no week 53 during the 2006-07 and 2007-08 seasons, therefore the week 53 data point for those seasons is an average of weeks 52 and 1.
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.4% to 4.3%. One region 
(Region IV) reported 4.3% of outpatient visits for ILI, which is above its region-specific baseline of 
2.0%, while the remaining nine regions reported percentages of visits for ILI below region-specific 
baseline levels.   
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:  The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
both seasonal influenza and 2009 influenza A (H1N1) viruses and does not measure the severity of 
influenza activity. 
 
During week 34, the following influenza activity was reported: 
 Widespread influenza activity was reported by Puerto Rico and six states (Alabama, Alaska, 
Florida, Georgia, Mississippi, and South Carolina). 
 Regional influenza activity was reported by 13 states (Arizona, California, Colorado, 
Kentucky, Louisiana, Maryland, Nebraska, Nevada, New Jersey, North Carolina, Oklahoma, 
Tennessee, and Virginia). 
 Local influenza activity was reported by the District of Columbia and 10 states (Arkansas, 
Hawaii, Kansas, Montana, New Mexico, Ohio, Pennsylvania, Texas, Washington, and West 
Virginia). 
 Sporadic activity was reported by 19 states (Connecticut, Delaware, Idaho, Illinois, Indiana, 
Iowa, Massachusetts, Michigan, Minnesota, Missouri, New Hampshire, New York, North 
Dakota, Oregon, South Dakota, Utah, Vermont, Wisconsin, and Wyoming). 
 No influenza activity was reported by two states (Maine and Rhode Island). 
 Guam and the U.S. Virgin Islands did not report. 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: September 4, 2009. 
 
